»ùÒòÇóýÔØÌå¹¹½¨
ЧÀÍÏêÇé
| ЧÀÍÀàÐÍ | ÇóýÂý²¡¶¾ÔØÌå/ÇóýÏÙ²¡¶¾ÔØÌå/ÇóýÏÙÏà¹Ø²¡¶¾ÔØÌå/ÇóýË²×ªÔØÌå |
|---|---|
| ½»¸¶±ê×¼ | 1.ÖÊÁ£Í¼Æ×2.ÖÊÁ£²âÐòЧ¹û3.ÖÊÁ£À©Ôö²Ù×÷˵Ã÷4.ÖÊÁ££¨ÈýÌõsgRNA·Ö×°£© |
| ÖÜÆÚ/¼ÛÇ® |
¿ìÖÁ2ÖÜ£¬£¬£¬£¬£¬1800ÔªÆð |
Çóý¼Æ»®
-
ÒÆÂëÇóý
Õë¶Ô»ùÒòµÄ±àÂëÇøÇ°¶ËÉè¼ÆsgRNA£¬£¬£¬£¬£¬ÊµÏÖ¼î»ù·Ç3µÄ±¶ÊýµÄindel
-
´óƬ¶ÏÇóý
Õë¶Ô»ùÒòÉè¼ÆsgRNA£¬£¬£¬£¬£¬ÊµÏÖ³¤Æ¬¶Ñþ³Øý
-
СƬ¶ÏÇóý
Õë¶Ô»ùÒòÉè¼ÆsgRNA£¬£¬£¬£¬£¬ÊµÏÖ¶ÌÆ¬¶Ñþ³Øý£¬£¬£¬£¬£¬²¢Ôì³ÉÒÆÂëÍ»±ä
ЧÀÍÓÅÊÆ
¸ß»îÐÔµÄCas9ÖÊÁ£
¸ßЧµÄsgRNAÉè¼Æ
¶àÖÖÇóýÖÊÁ£ÀàÐÍ
¿ÆÑ§Éè¼Æ
½»¸¶±ê×¼
| 1 | ÖÊÁ£Í¼Æ× |
|---|---|
| 2 | ÖÊÁ£²âÐòЧ¹û |
| 3 | ÖÊÁ£À©Ôö²Ù×÷˵Ã÷ |
| 4 | ÖÊÁ££¨ÈýÌõsgRNA·Ö×°£© |
ÖÊÁ£Í¼Æ×


Advantage and Characteristic
Optimazied Strategy
Optimazied Strategy
Optimazied Strategy
Optimazied Strategy
²Î¿¼ÎÄÏ×
MIA PaCa-2ºÍPANC-1ϸ°ûÖÐÇóýFUT8»ùÒò
ÒÈÏÙµ¼¹ÜÏÙ°©(Pancreatic ductal adencarcinoma, PDAC)ÊÇÒ»ÖÖ¼«Æä¶ñÐÔµÄÖ×Áö£¬£¬£¬£¬£¬Õ¼ËùÓÐÒÈÏÙ°©µÄ90%¡£¡£¡£¡£¡£¡£Ñо¿Åú×¢£¬£¬£¬£¬£¬°©Ï¸°ûÍâòµÄÒì³£ÌÇ»ù»¯×ª±äÓëÖ×ÁöÏ£ÍûºÍ×ªÒÆÕýÏà¹Ø£¬£¬£¬£¬£¬α1,6-ÑÒÔåÌÇ»ù×ªÒÆÃ¸£¨FUT8£©ÊÇÈÏÕæ´ß»¯½¹µãÑÒÔåÌÇ»ù»¯µÄÒªº¦Ã¸£¬£¬£¬£¬£¬ÆäÔÚ¶àÖÖ¶ñÐÔÖ×ÁöÖеıí´ïºÍ¼¤»îÒì³££¬£¬£¬£¬£¬Óë¶àÖÖÐÄÀíºÍ²¡ÀíÀú³ÌÏà¹Ø£¬£¬£¬£¬£¬Ö»¹ÜFUT8ÔÚÆäËûÀàÐ͵ݩ֢ÖеÄ×÷ÓÃÒѱ»ÊӲ쵽£¬£¬£¬£¬£¬µ«ÆäÔÚPDAC¶ñÐÔת»¯ÖеÄÏêϸ·Ö×Ó»úÖÆºÍ×÷ΪDZÔÚÖÎÁưеãµÄ¿ÉÄÜÐÔÉв»ÇåÎú¡£¡£¡£¡£¡£¡£
Ñо¿Ö°Ô±Ê¹ÓÃCRISPR/Cas9ϵͳÔÚMIA PaCa-2ºÍPANC-1ϸ°ûÖÐÇóýFUT8»ùÒò£¬£¬£¬£¬£¬Í¨¹ýTranswellǨáãʵÑéºÍ´´ÉËÓúºÏʵÑéÆÀ¹ÀFUT8-KOϸ°ûµÄǨáãÄÜÁ¦£¬£¬£¬£¬£¬Í¨¹ýMTTʵÑéºÍ¼¯ÂäÐγÉʵÑéÆÀ¹ÀFUT8-KOϸ°ûµÄÔöÖ³ÄÜÁ¦£¬£¬£¬£¬£¬²¢¼ì²âÁËFUT8-KOϸ°ûÖа©Ö¢¸Éϸ°û±ê¼ÇÎïµÄ±í´ïˮƽ¡£¡£¡£¡£¡£¡£Ð§¹ûÏÔʾ£¬£¬£¬£¬£¬ÓëÒ°ÉúÐÍϸ°ûÏà±È£¬£¬£¬£¬£¬FUT8-KOϸ°ûµÄǨáãÄÜÁ¦¡¢ÔöÖ³ºÍ¼¯ÂäÐγÉÄÜÁ¦ÏÔÖø½µµÍ£¬£¬£¬£¬£¬FUT8-KOϸ°ûÖа©Ö¢¸Éϸ°û±ê¼ÇÎïµÄ±í´ï½µµÍ¡£¡£¡£¡£¡£¡£FUT8»ùÒòÇóýϸ°ûÕ¹ÏÖÁËFUT8ÔÚÒÈÏÙ°©ÖеÄÖ÷Òª×÷Ó㬣¬£¬£¬£¬Ö¤ÊµÎúFUT8¿ÉÄÜÊÇÒÈÏÙ°©ÖÎÁƵÄÒ»¸öDZÔڰе㣬£¬£¬£¬£¬ÎªÎ´À´µÄÒÈÏÙ°©ÖÎÁƲßÂÔÌṩÁËеÄÊӽǡ£¡£¡£¡£¡£¡£
¾«Ñ¡¿Í»§ÎÄÕÂ
Deep whole-genome analysis of 494 hepatocellular carcinomas
È«ÇòÁè¼ÝÒ»°ëµÄ¸Îϸ°û°©£¨HCC£©²¡Àý±¬·¢ÔÚÖйú£¬£¬£¬£¬£¬µ«ÏÖÔÚÕë¶ÔÖйúÈËȺÖÐÒÒÐ͸ÎÑײ¡¶¾£¨HBV£©Ïà¹ØHCCµÄÈ«»ùÒò×éÆÊÎöÑо¿ºÜÊÇÓÐÏÞ¡£¡£¡£¡£¡£¡£ÎªÁËÍ»ÆÆÕâÖÖÏÞÖÆ£¬£¬£¬£¬£¬Ñо¿Ö°Ô±Æô¶¯ÁË“Öйú¸Î°©Í¼Æ×ÏîÄ¿”£¨CLCA£©£¬£¬£¬£¬£¬Ö¼ÔÚ¶ÔÖйúÈËȺÖеÄHCC¾ÙÐдó¹æÄ£µÄÈ«»ùÒò×éÆÊÎöÒÔÃ÷È·ÆäÆæÒìµÄ·¢²¡»úÖÆºÍ½ø»¯Àú³Ì¡£¡£¡£¡£¡£¡£¸ÃÏîÄ¿¶Ô494ÀýHCCÖ×ÁöÑù±¾¾ÙÐÐÁËÉî¶ÈÈ«»ùÒò×é²âÐò£¨Æ½¾ù²âÐòÉî¶ÈΪ120×£©£¬£¬£¬£¬£¬²¢ÆÊÎöÁËÆ¥ÅäµÄ±ÈÕÕѪҺÑù±¾£¬£¬£¬£¬£¬Õ¹ÏÖÁËHBVÏà¹ØHCCµÄÏêϸ»ùÒò×éÌØÕ÷¡£¡£¡£¡£¡£¡£Ñо¿·¢Ã÷£¬£¬£¬£¬£¬³ýÁËÒÑÖªµÄ±àÂëÇøÇý¶¯»ùÒò£¨ÈçTP53ºÍCTNNB1£©Í⣬£¬£¬£¬£¬»¹±£´æ6¸öеıàÂëÇøÇý¶¯»ùÒò£¨°üÀ¨FGA£©ºÍ31¸ö·Ç±àÂëÇøÇý¶¯»ùÒò¡£¡£¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬£¬Ñо¿»¹Õ¹ÏÖ5ÖÖеÄÍ»±äÌØÕ÷£¨°üÀ¨SBS_H8£©£¬£¬£¬£¬£¬ÒÔ¼°HBVÕûºÏÐγÉϸ°ûÍâ»·×´DNA£¨ecDNA£©µÄÕ÷Ï󣬣¬£¬£¬£¬ÕâЩecDNA¿Éµ¼Ö°©»ùÒòÀ©ÔöºÍ±í´ïÔöÌí¡£¡£¡£¡£¡£¡£Í¨¹ý¹¦Ð§Ñé֤ʵÑ飬£¬£¬£¬£¬Ñо¿Ö°Ô±Ö¤ÊµÁËFGA¡¢PPP1R12BºÍKCNJ12µÈ»ùÒòµÄÍ»±äÄܹ»ÏÔÖøÓ°ÏìHCCϸ°ûµÄÔöÖ³¡¢Ç¨áãºÍÇÖÏ®ÄÜÁ¦¡£¡£¡£¡£¡£¡£ÕâÏîÑо¿Ð§¹û²»µ«¸»ºñÁËÈËÃǶÔHCC»ùÒò×éѧµÄÃ÷È·£¬£¬£¬£¬£¬Ò²ÎªHCCµÄÕï¶ÏºÍÖÎÁÆÌṩÁËеÄDZÔڰе㡣¡£¡£¡£¡£¡£

ºòÑ¡Çý¶¯Òò×Ӹſö
Targeted Macrophage CRISPR-Cas13 mRNA Editing in Immunotherapy for Tendon Injury
¼¡ëìËðÉ˼±ÐÔÑ×Ö¢ÆÚÖУ¬£¬£¬£¬£¬¾ÞÊÉϸ°ûÌ«¹ý¼¤»î»áµ¼Ö±àÂë¹ÇÇÅÂѰ×OPNµÄSPP1¹ý±í´ï£¬£¬£¬£¬£¬Ó°Ïì×éÖ¯ÔÙÉú¡£¡£¡£¡£¡£¡£CRISPR-Cas13ÓÉÓÚ¾ßÓÐRNA±à¼ºÍ¿ìËÙ½µ½âµÄÄÜÁ¦£¬£¬£¬£¬£¬ÔÚ×éÖ¯ÐÞ¸´·½Ãæ¾ßÓÐÖØ´óDZÁ¦£¬£¬£¬£¬£¬µ«È±·¦ºÏÊÊÓÐÓõĵÝËÍÒªÁì¡£¡£¡£¡£¡£¡£¶Ô´Ë£¬£¬£¬£¬£¬Ñо¿Ö°Ô±ÏµÍ³É¸Ñ¡ÁËÕë¶Ô¾ÞÊÉϸ°ûµÄÑôÀë×Ó¾ÛºÏÎ£¬£¬£¬£¬¿ª·¢ÁËÒ»ÖÖÄܹ»¸ßЧµÝËÍCas13ºËÌǺËÂѰ׸´ºÏÎCas13 RNP£©½øÈë¾ÞÊÉϸ°ûµÄÄÉÃ×´ØÔØÌå¡£¡£¡£¡£¡£¡£Í¨¹ý·´Ó¦ÐÔÑõÖÖ£¨ROS£©ÏìÓ¦ÐÔÊÍ·Å»úÖÆ£¬£¬£¬£¬£¬¸ÃϵͳÄܹ»ÔÚ¼¡ëìËðÉ˵ļ±ÐÔÑ×֢΢ÇéÐÎÖÐÌØÒìÐÔÒÖÖÆ¾ÞÊÉϸ°ûÖÐSPP1µÄ¹ý±í´ï¡£¡£¡£¡£¡£¡£ÊµÑéЧ¹ûÅú×¢£¬£¬£¬£¬£¬ÕâÖÖ°ÐÏò²ßÂÔÏÔÖøïÔÌÁËËðÉËÓÕµ¼µÄSPP1±¬·¢¾ÞÊÉϸ°ûµÄ·ºÆð£¬£¬£¬£¬£¬½µµÍÁ˳ÉÏËάϸ°ûµÄ¼¤»î£¬£¬£¬£¬£¬²¢¼õÇáÁ˼¡ëìÖÜΧµÄÕ³Á¬Ðγɡ£¡£¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬£¬¸ÃÑо¿»¹Õ¹ÏÖÁËSPP1ͨ¹ýCD44/AKTÐźÅͨ·Ôö½ø³ÉÏËάϸ°û»î»¯ºÍǨáãµÄ»úÖÆ£¬£¬£¬£¬£¬²¢Í¨¹ýÒÖÖÆÕâһͨ·ÓÐÓûº½âÁ˼¡ëìËðÉ˺óµÄÕ³Á¬ÎÊÌâ¡£¡£¡£¡£¡£¡£

ÓÃÓÚPAÖÎÁƵľÞÊÉϸ°ûÃâÒß΢ÇéÐ줻îmRNA±à¼²ßÂÔµÄʾÒâͼ
Electrical stimulation of piezoelectric BaTiO3 coated Ti6Al4V scaffolds promotes anti-inflammatory polarization of macrophage and bone repair via MAPK/JNK inhibition and OXPHOS activation
¼¹ËèËðÉË£¨SCI£©ÊÇÒ»ÖÖµ¼Ö¸ÐÊÜ×ÔÖ÷Éñ¾ºÍÔ˶¯¹¦Ð§µÄÓÀÊÀÐÔË𺦵ÄÑÏÖØÖ²ÐÐÔ¼²²¡¡£¡£¡£¡£¡£¡£¸Éϸ°ûÁÆ·¨£¬£¬£¬£¬£¬ÓÈÆäÊǼä³äÖʸÉϸ°û£¨MSCs£©£¬£¬£¬£¬£¬ÔÚSCIÖÎÁÆÖÐÕ¹ÏÖ³öÖØ´óDZÁ¦µ«ÆäÔÙÉúÄÜÁ¦ÓÐÏÞ£¬£¬£¬£¬£¬ÕâÏÞÖÆÁËÆäÔÚ×éÖ¯ÔÙÉúÖеÄÓ¦Óᣡ£¡£¡£¡£¡£Ñо¿ÍŶÓÊӲ쵽ABPCsÑÜÉúµÄEVs£¨EVsABPC£©¿ÉÄÜЯ´øÔö½ø×éÖ¯ÔÙÉúµÄÉúÎï»îÐÔÐźţ¬£¬£¬£¬£¬Òò´ËËûÃÇ´Ó¹½ÇÑ¿»ù×æÏ¸°û£¨ABPCs£©ÖÐÌáÈ¡²¢ÐÞÊÎÁËϸ°ûÍâÄÒÅÝ£¨EVsABPC£©£¬£¬£¬£¬£¬²¢½«ÆäÓ¦ÓÃÓÚ¼¹ËèËðÉË£¨SCI£©µÄÖÎÁÆÑо¿¡£¡£¡£¡£¡£¡£Ñо¿Ö°Ô±·¢Ã÷EVsABPCÄܹ»ÏÔÖøÔöÇ¿Éñ¾¸Éϸ°û£¨NSCs£©µÄÔöÖ³£¬£¬£¬£¬£¬Ôö½øÖáÍ»Éú³¤£¬£¬£¬£¬£¬ïÔÌÉñ¾ÔªµòÍö£¬£¬£¬£¬£¬²¢Í¨¹ýµ÷ÀíÑ×Ö¢·´Ó¦½«¾ÞÊÉϸ°û´Ó´ÙÑ×µÄM1Ðͼ«»¯Îª¿¹Ñ×µÄM2ÐÍ¡£¡£¡£¡£¡£¡£±ðµÄ£¬£¬£¬£¬£¬¾Óɹ¤³Ì»¯Ë¢ÐµÄEVsABPC£¨Í¨¹ý¼¤»îϸ°û´©Í¸ëÄÐÞÊΣ©Äܹ»¸üÓÐÓõذÐÏòSCIËðÉ˲¿Î»£¬£¬£¬£¬£¬ÏÔÖø¸ÄÉÆÉñ¾ÔÙÉúºÍÔ˶¯¹¦Ð§»Ö¸´¡£¡£¡£¡£¡£¡£ÕâЩЧ¹ûÅú×¢£¬£¬£¬£¬£¬EVsABPCÊÇÒ»ÖÖ¼«¾ßDZÁ¦µÄSCIÖÎÁƺòÑ¡¼Æ»®¡£¡£¡£¡£¡£¡£

ͼ½âÕªÒª
Generation of recombinant antibodies by mammalian expression system for detecting S-metolachlor in environmental waters
S-Òì±û¼×²Ý°·£¨S-MET£©ÊÇÎÒ¹úÉú²úºÍʹÓÃÁ¿×î´óµÄ³ý²Ý¼ÁÖ®Ò»£¬£¬£¬£¬£¬Æä»¯Ñ§ÌØÕ÷µ¼ÖÂÆä¿ÉÔÚÍÁÈÀÖг¤ÆÚ±£´æÒÔ¼°ÈÝÒ×ͨ¹ýÁÜÈܺͳÁ½µÎÛȾµØ±íË®ºÍµØÏÂË®£¬£¬£¬£¬£¬×îÖÕÓ°ÏìÖ²ÎïÉú³¤ºÍͨ¹ýʳÎïÁ´Î£º¦ÈËÀàÉúÃü¿µ½¡¡£¡£¡£¡£¡£¡£¼øÓÚÏÖÓмì²âÒªÁìµÄ¾ÖÏÞÐԺͶԸßЧÆÊÎö¼¼ÊõµÄÆÈÇÐÐèÇ󣬣¬£¬£¬£¬¸ÃÑо¿ÒÔS-metolachlorΪ¹¤¾ß£¬£¬£¬£¬£¬Ê¹Óò¸È鶯Îï±í´ïϵͳÌìÉúÏà¹ØÖØ×鿹Ìå¡£¡£¡£¡£¡£¡£ÔÚÀֳɱí´ï¿¹ÌåµÄ»ù´¡ÉÏ£¬£¬£¬£¬£¬Àֳɽ¨ÉèÁË»ùÓÚÕâЩ¿¹ÌåµÄÃâÒ߯ÊÎöÒªÁ죬£¬£¬£¬£¬ÓÃÓÚ¼à²âÇéÐÎË®ÑùÖеÄS-Òì±û¼×²Ý°·²ÐÁô¡£¡£¡£¡£¡£¡£icELISAЧ¹ûÏÔʾ£¬£¬£¬£¬£¬ÖØ×鿹ÌåµÄѸËٶȺÍÌØÒìÐÔÓëÇ×±¾µ¥¿¹ÏàËÆ£¬£¬£¬£¬£¬¿É¼á³ÖÔÓеÄÉúÎïѧ»îÐÔ£¬£¬£¬£¬£¬¹ØÓڽˮ¡¢Å©ÌïË®ºÍ×ÔÀ´Ë®ÖеÄS-MET£¬£¬£¬£¬£¬¾ßÓÐÓÅÒìµÄ׼ȷÐÔºÍÖØ¸´ÐÔ¡£¡£¡£¡£¡£¡£

ͼ½âÕªÒª
Dumbbell probe initiated multi-rolling circle amplification assisted CRISPR/Cas12a for highly sensitive detection of clinical microRNA
ϸСRNA£¨miRNA£©ÊÇÒ»ÀàСµÄ·Ç±àÂëRNA·Ö×Ó£¬£¬£¬£¬£¬Í¨¹ýÓëÌØ¶¨°Ð»ùÒòµÄÐÅʹRNA£¨mRNA£©Ï໥×÷ÓÃÀ´µ÷¿Ø»ùÒò±í´ï¡£¡£¡£¡£¡£¡£miRNAÔÚ¶àÖÖ¼²²¡µÄ±¬·¢¡¢Éú³¤Àú³ÌÖÐÊÎÑÝ×ÅÖ÷Òª½ÇÉ«£¬£¬£¬£¬£¬±»ÒÔΪÊǼ«¾ßDZÁ¦µÄ¼²²¡ÉúÎï±ê¼ÇÎï¡£¡£¡£¡£¡£¡£¸ÃÑо¿Ê¹ÓÃCRISPR/Cas12a¿ª·¢ÁËÒ»ÖÖΪDBmRCAµÄÐÂÐÍmiRNA¼ì²â¼¼Êõ¡£¡£¡£¡£¡£¡£¸Ã¼¼ÊõʹÓÃÎÞÅþÁ¬Ã¸µÄÑÆÁå̽ÕëºÍ¸ßѸËٶȵÄCRISPR/Cas12aÐźÅÊä³ö²ßÂÔ£¬£¬£¬£¬£¬ÊµÏÖÁËÔÚ30·ÖÖÓÄÚ¶ÔmiRNAµÄ¸ß¾«¶È¶¨Á¿ÆÊÎö¡£¡£¡£¡£¡£¡£Ñо¿ÍŶÓͨ¹ýÁÙ´²Ñù±¾ÑéÖ¤Á˸ü¼ÊõµÄÓÐÓÃÐÔ£¬£¬£¬£¬£¬·¢Ã÷miR-200aºÍmiR-126Ôڷΰ©×éÖ¯Öеıí´ïˮƽÏÔÖø½µµÍ£¬£¬£¬£¬£¬ÇҸü¼ÊõÓë¹Å°åÒªÁìЧ¹ûÒ»Ö¡£¡£¡£¡£¡£¡£DBmRCA¼¼Êõ¾ßÓÐʱ¼äЧÂʸߡ¢Ñ¸ËÙ¶ÈÇ¿ºÍ²Ù×÷Á÷³Ì¼ò»¯µÈÓŵ㣬£¬£¬£¬£¬ÎªÁÙ´²miRNAÆÊÎöÌṩÁËÒ»ÖÖ¿É¿¿µÄ¹¤¾ß£¬£¬£¬£¬£¬ÓÐÍûÖúÁ¦·Î°©µÄÔçÆÚÕï¶ÏºÍÖÎÁÆ¡£¡£¡£¡£¡£¡£

ͼ½âÕªÒª
ÍêÃÀÕæÈË